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Abstract 
Adverse immune reactions prevent clinical translation of numerous implantable devices and 
materials. Although inflammation is an essential part of tissue regeneration, chronic 
inflammation ultimately leads to implant failure. In particular, macrophage polarity steers the 
microenvironment towards inflammation or wound healing via the induction of M1 and M2 
macrophages, respectively. Here, we demonstrated that macrophage polarity within 
biomaterials can be controlled through integrin mediated interactions between human 
monocytic THP-1 cells and collagen-derived matrix. Surface marker, gene expression, 
biochemical and cytokine profiling consistently indicated that THP-1 cells within a biomaterial 
lacking cell attachment motifs yielded pro-inflammatory M1 macrophages, whereas 
biomaterials with attachment sites in the presence of IL-4 induced an anti-inflammatory M2 
like phenotype and propagated the effect of IL-4 in induction of M2 like macrophages. 
Importantly, integrin α2β1 played a pivotal role as its inhibition blocked the induction of M2 
macrophages. The influence of the microenvironment of the biomaterial over macrophage 
polarity was further confirmed by its ability to modulate the effect of IL-4 and 
lipopolysaccharide, which are potent inducers of M2 or M1 phenotypes, respectively. Thus, our 
study represents a novel, versatile and effective strategy to steer macrophage polarity through 
integrin mediated three-dimensional (3D) microenvironment for biomaterial-based 
programming. This development has wide implications for controlling inflammation, 
angiogenesis, cell proliferation, and tissue regeneration for a myriad of applications including 
tissue engineered implants, drug delivery vehicles, and implantable devices. 
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1. Introduction 
Inflammation is an inevitable consequence of implantation and is closely linked to the 
implant’s clinical outcome. Upon implantation, immune cells migrate to the implantation site 
and initiate a localized inflammatory response [1]. Although inflammation is an indispensable 
element in tissue regeneration, an intense or chronic inflammatory response will significantly 
limit natural healing. Moreover, detrimental inflammatory responses can result in fibrotic 
capsule formation around the implant and result in ultimately failure of the implants [1b]. Thus, 
the ability to actively control inflammation in regenerating tissues and implanted medical 
devices represents a major yet unsolved challenge. 
Among the variety of immune cells, monocytes and macrophages play a particularly 
critical role that determines successful tissue-implant integration or implant failure [2]. 
Specifically, macrophage polarity strongly influences clinical outcome through the balance 
between pro-inflammatory M1 and regenerative M2 macrophages. Classically activated M1 
macrophages are associated with a pro-inflammatory response [3]. In contrast, alternatively 
activated M2 macrophages are associated with an anti-inflammatory response, which induces 
angiogenesis and proliferation [3b, 4]. Therefore, harnessing macrophage polarity presents a 
unique opportunity to control inflammation, prevent rejection and accelerate integration of 
biomaterials and medical devices. 
Macrophage polarization is most commonly controlled via exposure to biochemical 
factors. Specifically, the M1 macrophage phenotype is typically induced through interferon 
gamma (IFNγ) or lipopolysaccharide (LPS) stimulation, while the M2 macrophage phenotype 
is typically induced through Interleukin-4 (IL-4) or Interleukin-13 (IL-13) stimulation [5]. 
However, these approaches are not easily translated into in vivo approaches due to the challenge 
of delivery, temporal nature of the stimulus and risk of adverse effects. 
Recent advances in biomaterials science have identified that a biomaterial’s design can 
be leveraged to instruct the host’s immune system [6]. For example, novel biomaterial surfaces 
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[7], improved immune-instructive biomaterials [8] and incorporated immune modulating cells 
(e.g. stem cells) [9] could influence the wound healing process. Within the same context, there 
are several studies in which the phenotype of macrophages inside different 3D biomaterial 
environment has been studied [10]. In addition, several physical factors have recently been 
reported to regulate macrophage polarization [11]. These factors include biomaterial pore size 
[12], mechanical stimulation [13] and extracellular matrix proteins (ECM) [14] amonst others. 
However, the underlying mechanisms of how biomaterials steer macrophage polarity has 
remained poorly understood. This has obscured the underlying biomaterial design principles, 
which has limited our capability to engineer smart biomaterials with the ability to steer 
macrophage polarity. 
Cell adhesion is an essential communication between cells and their microenvironment. 
This form of interaction is known to regulate numerous aspects of cellular behavior including 
migration, proliferation, morphogenesis and differentiation [15]. It is well established that 
surface structure, pore size and ECM influence a cell’s ability to adhere to substrates through 
e.g. integrin interactions [16]. Indeed, integrins are well-known to influence inflammation [17] 
and fibrosis [18]. However, their role in monocyte to macrophage differentiation and particularly 
macrophage polarization is yet to be fully understood. Here, we hypothesized that integrin 
mediated cell-biomaterial interactions could play a key role in macrophage polarization. Given 
that in vivo these events take place in the context of ECM and in 3D, obtaining a clear 
understanding of the role of integrins in macrophage polarization in a 3D microenvironment 
will be more physilogically relevant than in a 2D environment [19]. Therefore, in this study, we 
have used two distinct hydrogel systems to probe the effect of cell-biomaterial interactions on 
macrophage polarization in a 3D environment. Specifically, we have set-out to investigate 
whether macrophage polarity can be controlled through integrin mediated biomaterial-based 
programming. 
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2. Results and Discussion 
2.1 Characterization of two distinct monocyte laden 3D hydrogels  
The effect of 3D biomaterial environment on monocyte behavior has remained largely 
unknown. We therefore explored the behavior of human monocytic THP-1 cells encapsulation 
in two distinct hydrogel systems, namely gelatin methacryloyl (GelMA) and poly (ethylene 
glycol) diacrylate (PEGDA).  
First, we investigated the microenvironment as presented by GelMA by varying the 
polymer concentrations from 5 to 15% (w/v). Increasing the GelMA concentration from 5 to 
15% (w/v) increased the hydrogel’s crosslinking density and compressive modulus due to an 
inverse relation between the GelMA concentration and its porosity, as previously described by 
our group [20]. In particular, the compressive modulus increased from 2.96 ± 0.28 kPa to 25.82 
± 1.50 kPa (Fig. S1). Upon encapsulation, THP-1 cells in the softer 5% GelMA hydrogels 
demonstrated significantly higher levels of cell survival (Fig. S2 A and B) as well as increased 
metabolic activities compared to those encapsulated in the stiffer 10% and 15% GelMA 
hydrogels (Fig. S3). In addition, the swelling characteristics of a hydrogel are important in its 
biocompatibility through affecting various parameters including mass transport and mechanical 
properties[21]. We performed a swelling test for GelMA hydrogels at various concentrations. 
The 5% GelMA hydrogels had significantly higher levels of swelling ratio compared to the 
10% and 15% GelMA hydrogels. The low cell viability and metabolic activities of THP-1 cells 
within both 10 and 15% (w/v) GelMA can be explained by increased stiffness values and 
reduced swelling ratio when using relatively high (w/v) amounts of GelMA. These results 
underlined THP-1 cells' sensitivity to their microenvironment's physical properties (e.g. 
stiffness and mass transport etc) which could in turn impact the biological processes (Fig. S4). 
In line with our finding, it has previously been reported that the stiffness of 2D hydrogels 
correlates with the number of monocytes that are differentiated into macrophages [22]. Based on 
our results, all subsequent experiments were performed with 5% (w/v) GelMA.  
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Monocytes can be chemically driven into a regenerative M2 macrophage phenotype 
through exposure to IL-4 [23]. Analysis of release kinetics demonstrated that GelMA acted as a 
proper cytokine reservoir with a sustained release of IL-4 over 7 days (Fig. S5). Even though 
macrophages are highly plastic and can show phenotypic changes within hours; the 
differentiation or induction in in vitro conditions is typically done for 6-8 days. Future studies 
could focus on better understanding of the kinetics of the observed phenotypical changes [24]. 
Thus the IL-4 release profiles from the hydrogel provides an ample time window to present 
monocytes with a microenvironment that is conducive to macrophage polarization. 
Although GelMA appeared highly suitable to study macrophage polarization within a 
3D environment, we simultaneously explored a distinct second hydrogel system (10% (w/v) 
PEGDA) to exclude possible biomaterial-based bias. To maximize the similarities between the 
two hydrogel systems, we matched the compressive modulus of 10% (w/v) PEGDA to that of 
5% GelMA (Fig. S6) and minimized the differences in IL-4 release (Fig. S7). However, the two 
hydrogel systems remained inherently distinct in that unlike PEGDA, GelMA contains cell 
attachment sites. 
THP-1 cells were used as a surrogate for human monocytes to ensure reproducibility of 
our findings by eliminating potential donor-to-donor variation. Monocytic cells were 
encapsulated in PEGDA and GelMA hydrogels with or without IL-4 incorporation to examine 
their morphological phenotype over 6 days. Intriguingly, the size of the THP-1 cellsin GelMA 
hydrogels became progressively larger (Fig. 1A). Supplementation of IL-4 to GelMA hydrogels 
further exacerbated this cell enlargement. In contrast, the size of the THP-1 cellsin PEGDA 
hydrogels remained the same under all conditions and time points. Quantitative analysis of the 
cell diameters confirmed that cells within GelMA (15.58 ± 0.63 μm) and IL-4 incorporated 
GelMA (20.31 ± 0.89 μm) hydrogels became significantly larger than cells within PEGDA 
(9.99 ± 0.34 μm) and IL-4 incorporated PEGDA (10.41 ± 0.35 μm)) after 6 days of culture (Fig. 
1B). Cell size distribution analysis revealed that while GelMA hydrogels created a shift in the 
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general cell size population, IL-4 yielded an additional enrichment of the largest cell fraction 
(Fig. 1C). Taken together, GelMA hydrogel’s bioactive microenvironment influenced the THP-
1 cells’ shape, whereas the bio-inert microenvironment of PEGDA did not. Thus, hydrogel 
composition has been found to play a significant role on the size of the encapsulated THP-1 
cells. Even though no previous study has definitively demonstrated the effect of monocyte size 
on macrophage polarity, it is well documented that cell size and cell shape [25] are important 
determinants of cellular events including differentiation, function, proliferation, and apoptosis 
[26]. 
 
2.2 Hydrogel composition strongly affects expression of M1-M2 macrophage surface markers  
Next, we set out to determine whether the observed differences in cell size between 
hydrogel systems correlated with a change in macrophage polarity. To this end, the expression 
of M1-M2 macrophage surface markers on human monocytic THP-1 cell cultured in PEGDA 
or GelMA hydrogels were visualized in the presence or absence of IL-4, the M2 macrophage 
inducing agent (Fig. 1D). The well-established surface biomarkers CD86 and CD206 were 
chosen to identify M1 and M2 macrophages, respectively [27]. Semi-quantitative image analysis 
demonstrated that after 6 days THP-1 cells in GelMA expressed a notably high level of CD206 
as well as less intense yet detectable levels of CD86 (Fig. 1E). As expected, incorporation of 
IL-4 in GelMA hydrogels drove the induction of M2 macrophages as evidenced by increasing 
CD206 and decreasing CD86 expression. In sharp contrast, THP-1 cellsin PEGDA hydrogels 
expressed high levels of CD86 whereas the CD206 levels were undetectable. Surprisingly, 
incorporation of IL-4 in PEGDA did not alter the expression of either CD86 or CD206.  
To further confirm the observed effects of PEGDA and GelMA hydrogels on 
macrophage polarity, we fingerprinted the THP-1 cells monocytes by profiling their M1-M2 
gene expression. Indeed, encapsulation of THP-1 cells in PEGDA resulted in increased 
expression of the genes encoding M1 inducing transcription factor IRF5 and M1 related 
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cytokine IL6, whereas mRNA levels of IRF5 and IL6 remained unaffected when cells were 
encapsulated in GelMA hydrogels (Fig. 1F). Furthermore, human monocytic THP-1 cells 
encapsulated in GelMA hydrogels demonstrated increased gene expression of M2 related 
cytokine IL10 expression (Fig. 1G) [28]. Similar to our CD86 observations, the incorporation of 
IL-4 in PEGDA hydrogels was unable to significantly increase IL10 and M2 inducing 
transcription factor STAT6 expression levels, whereas IL-4 incorporated GelMA hydrogels 
strongly increased their gene expression. Collectively, these results supported the stipulation 
that a biomaterial’s composition can prime monocytes towards either a M1 or M2 phenotype. 
By extension, it might therefore be possible to program the immune system to either pro 
or anti-inflammatory responses purely based on the design of a biomaterial. In particular, IL-4 
incorporated GelMA hydrogels induce regenerative M2 macrophages, whereas IL-4 
incorporated PEGDA hydrogels induced pro-inflammatory M1 macrophages. PEGDA 
hydrogel’s M1 phenotype inducing effect is further underlined by its ability to block IL-4’s 
capacity to induce M2 macrophages. This is in line with recent studies showing that bio-inert 
PEGDA hydrogels can elicit strong immune response [29]. This observation is of interest as PEG 
is typically used for its immune-shielding properties, which is based on its mesh size and bio-
inert nature [30]. Regardless, recent studies are in line with our observation that the bio-inert 
PEGDA can elicit a strong immune response [29]. Consequently, by understanding how 
biomaterials affect macrophage polarity, we might improve our capability to design 
biomaterials with improved immunomodulatory properties. 
 
2.3 Hydrogel composition controls macrophage’s functional properties 
We then set out to confirm that the PEGDA hydrogel indeed robustly drives THP-1 cells  
into a functional M1 macrophage phenotype. To this end, we determined the expression of 
NOS2, NFKB and TNFA (Fig. 2A) as well as nitrite production (Fig. 2B), which are all 
indicative of M1 functionality. Human monocytic THP-1 cells encapsulated in PEGDA 
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hydrogels demonstrated higher expression levels for all four pro-inflammatory markers 
compared to cellss encapsulated in GelMA hydrogels. Unexpectedly, GelMA in the absence of 
IL-4 also guided pro-inflammatory responses, as noted by increased NOS2 and NFKB 
expressions compared to the control group. Nevertheless, IL-4 stimulation decreased the levels 
of all markers even further in GelMA hydrogels. However, the expression levels of NOS2, 
NFKB, TNFA, and nitrite from THP-1 cellsin PEGDA hydrogels remained largely unaffected 
after exposure of THP-1 cells to IL-4. In line with these observations, immunohistochemistry 
revealed that cells encapsulated in PEGDA hydrogels demonstrated intense positive staining 
for M1 marker iNOS [28d, 31] and negative for M2 marker Arginase-1 [28d, 32], whereas THP-1 
cells in GelMA demonstrated the exact opposite staining pattern (Fig. 2C and 2D). In addition, 
both PEGDA and GelMA hydrogels appeared to generate pro-inflammatory response even in 
the absence of a polarizing stimuli, with PEGDA having a stronger effect. Although the 
expression and role of iNOS and Arginase-1 are better defined in mice models; recent work 
have also reported their expression and function in human macrophages [31, 33].  
Our results demonstrate the potency of cell-biomaterial interactions to program 
monocytes into a specific polarized macrophage phenotype. Paradoxically, the data also 
suggests that bio-inert materials such as PEGDA hydrogels can elicit a pro-inflammatory 
immune response [29]. However, these pro-inflammatory responses induced in GelMA in the 
absence of IL-4 stimulation would not be able to explain the mechanism, clearly. Moreover, 
biomaterial composition can even prevent monocytes from responding to cytokines such as IL-
4 that would drive implant integration and tissue regeneration. The mechanism by which 
biomaterials can drive monocytes into such distinct macrophage phenotypes has remained 
largely unknown. However, we reasoned that our approach of simultaneously using two 
comparable (e.g. in terms of their mechanical properties and IL-4 release profiles) yet distinct 
hydrogel systems might yield valuable information on how biomaterials composition can 
control macrophage polarization.   
  
10 
 
 
2.4 Hydrogel composition determines macrophage cytokine releaseprofile  
To confirm the M1 and M2 fingerprints, we additionally visualized and semi-quantified 
the M1-M2 macrophage specific cytokine release profiles from human monocytic THP-1 cells 
encapsulated in either PEGDA or GelMA hydrogels in the presence of IL-4. In particular, the 
secretion of pro-inflammatory cytokines IL-1B, IL-6, and IL-16 as well as the anti-
inflammatory cytokines IL-1RA and IL-10 were investigated (Fig. 3A and 3B). THP-1 cells 
encapsulated in GelMA demonstrated significantly higher levels of all tested anti-inflammatory 
cytokines as compared to those encapsulated in PEGDA. Interestingly, no LPS stimulated THP-
1 cells encapsulated in GelMA also demonstrated a modest trend of higher expression levels of 
pro-inflammatory cytokines as compared to the M1 inducing PEGDA. 
It is of note that these experiments were performed in the presence of M2 inducing IL-
4, but in the absence of an M1 inducing factor. However, wound and implant sites naturally 
contain a combination of stimuli that favor both M1 and M2 polarization at different stages of 
healing. We therefore encapsulated THP-1 cells in PEGDA or GelMA hydrogels and exposed 
them to both LPS and IL-4, which drove M1 and M2 polarization, respectively. Remarkably, 
under these more biologically complex conditions, we observed that THP-1 cells in PEGDA 
hydrogels expressed significantly higher levels of all M1 related cytokines, whereas those in 
GelMA hydrogels expressed significantly higher levels of all M2 related cytokines (Fig. 3C and 
3D). In accordance with previous studies, although in 2D culture, the secretion of the pro-
inflammatory molecules IL-1β and TNF-α increased dramatically following human primary 
monocyte interactions with PEG-only hydrogel films as compared with tissue culture 
polystyrene (TCPS) [34]. In fact, supplementation of the M1 inducing LPS to THP-1 cells in 
GelMA hydrogels further increased the expression levels of M2 related cytokines while 
decreasing those of M1 related cytokines, as compared to IL-4 alone. In essence, these results 
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demonstrated that LPS simulation did not revert the M2 polarization of macrophages in GelMA 
in the presence of IL-4 and unexpectedly enhanced the polarization. 
 
2.5 Hydrogel composition affects on the THP-1 cells’ integrin expression and cytoskeletal 
organization 
A key difference between the hydrogels used in this study is the presence or absence of 
cell-adhesive motifs. Specifically, GelMA hydrogels contain cell adhesive sequences while 
PEGDA hydrogels do not. We therefore hypothesized that the difference in macrophage 
phenotype between the two hydrogel systems might be regulated through attachment and 
downstream signaling, which is mediated via integrin subunits and focal adhesions. To this end, 
we determined the relative gene expression levels of Focal Adhesion Kinase (PTK2), Vinculin 
(VCL), monocyte-related integrin receptors Integrin αD (ITGAD) and β2 (ITGB2), and collagen 
matrix-related integrin receptors Integrin α2 (ITGA2) and β1 (ITGB1) in cells encapsulated in 
PEGDA and GelMA hydrogels with or without IL-4. PEGDA hydrogel’s inability to provide 
binding sites was mirrored by the strong decrease in PTK2 expression levels compared to 
GelMA hydrogels and tissue culture plastic grown control samples. In contrast, GelMA 
hydrogels induced an increase in monocytes’ expression of PTK2 and VCL (Fig. 4A). Low 
levels of integrin αD and β2 – alternatively known as CD11d and CD18 – are correlated with 
monocyte migration, whereas high levels of these integrins are associated with pro-
inflammatory macrophages [35]. In line with this, monocytes encapsulated in PEGDA hydrogels 
showed significantly high levels of ITGAD and ITGB2 expressions, whereas the expressions 
of these integrin proteins were found to be low when encapsulated in GelMA hydrogels (Fig. 
4B). Such an increase in upregulation of integrin αDβ2 on monocytes/macrophages might be 
due to the stimulation of pro-inflammatory responses resulting from the IL-4 presence with 
lesser effects arising from the absence of available binding sites in PEGDA hydrogels. 
Migration and collagen attachment is mediated via integrins such as α2 and β1, which are also 
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known as CD49b and CD29 [36]. The expression of ITGA2 and ITGB1 were drastically 
upregulated in GelMA hydrogels but remained unchanged in PEGDA hydrogels (Fig. 4C). 
These results demonstrated that the composition of the biomaterial effectively determines 
human monocytic THP-1 cells’ expression of adhesion molecules. In addition to facilitating 
cell attachment, integrins also play an important and versatile role in multiple signaling 
pathways. Therefore, biomaterials can program the cellular response to a given 
microenvironment, which includes their response to e.g. macrophage polarizing cytokines. 
To investigate whether the changes in integrin expression translated to cytoskeletal 
changes, we measured the expression and distribution of vinculin and filamentous actin (F-
Actin) using immunocytochemistry. Vinculin is involved in the linkage of integrin adhesion 
molecules to the actin cytoskeleton. Therefore, Vinculin and F-Actin are both sensitive and 
responsive to biological and mechanical stimuli mediated via integrin-based cell attachment [37]. 
THP-1 cellsencapsulated in GelMA hydrogels showed intense staining for vinculin, whereas 
the staining of those encapsulated in PEGDA hydrogels were consistently below the detection 
limit (Fig. 4D). The latter result might be explained by the diminished biomechanical 
stimulation due to the lack of cell binding sites in PEGDA hydrogels. Furthermore, THP-1 
cellsin PEGDA hydrogels demonstrated clump-like cytoplasmic aggregates of F-Actin, which 
has been reported to correlate with monocyte-to-macrophage transition as well as the migration 
and function of various immune cells [38]. F-Actin staining of THP-1 cells in GelMA hydrogels 
revealed the presence of a prominent cortical shell, which has been reported to be indicative of 
M2 commitment [39]. Together, these results demonstrated that biomaterial induced changes in 
integrin expression effectively translated to – or tightly correlated with – marked changes in 
cell behavior and cytoskeletal organization.  
 
2.6 Integrin α2β1 mediated binding of THP-1 cells to biomaterials is required for M2 
macrophage polarization 
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Based on the significant changes in integrin expression and subsequent cytoskeletal 
reorganization, we hypothesized that integrins might potently affect downstream signaling 
pathways and thereby control macrophage polarity. To this end, THP-1 cellsencapsulated in 
GelMA hydrogels were exposed to a neutralizing antibody for integrin α2β1 in the presence or 
absence of the M2 inducing cytokine IL-4. Similar to our previous experiments, THP-1 cells in 
GelMA hydrogels expressed high levels of M1-related CD86 and low levels of M2-related 
CD206, and IL-4 supplementation further decreased CD86 to undetectable levels and 
significantly increased CD206 expression. Remarkably, blocking integrin α2β1 strongly 
increased CD86 expression and reduced CD206 expression below the detection limit, even in 
the presence of IL-4 (Fig. 5A and 5B). THP-1 cells encapsulated in GelMA hydrogels that were 
exposed to integrin α2β1 blocker therefore mirrored the behavior of human monocytic THP-1 
cells  encapsulated in PEGDA. Addition of non-inhibitory isotype control antibody was 
undistinguishable from the untreated control group. This suggested that the integrin α2β1 
induced polarization through its integrin α2β1 binding domain rather than its conserved 
antibody domain. Furthermore, immunohistochemical staining revealed that blocking integrin 
α2β1 lowered the expression of F-actin and Vinculin while reducing the cell size therefore more 
closely resembling THP-1 cells encapsulated in PEGDA hydrogels. Moreover, these results 
suggested the effective blocking of integrin α2β1 mediated binding and thus limiting cell-
biomaterial interactions (Fig. 5C). Moreover, this blockage mitigated the high levels of 
cytoskeletal related PTK2 and VCL expression in GelMA hydrogels, strongly increased 
expression of M1-related IRF5 and IL6, and decreased expression of M2-related STAT6 and 
IL10 (Fig. 5D). In summary, integrin α2β1 appeared to play a pivotal role in macrophage 
polarization (Fig. 5E). In particular, IL-4 incorporated GelMA hydrogel biomaterials were 
observed to drive monocytes into the M2 macrophage phenotype through integrin α2β1 
attachment, most likely via STAT6 activation. The inability of monocytes to attach to 
biomaterials via integrin α2β1 – either through pharmacological blockage or absence of 
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available binding sites – results in the generation of M1 macrophages, most likely through IRF5 
activation. This might also suggest that M1 is potentially a default phenotype. 
To confirm that the observation of integrin α2β1-mediated macrophage polarization was 
not restricted to the THP-1 monocytic cell line, we also seeded human primary monocytes on 
plates coated with integrin α2β1 peptide (the type I collagen α1(I)-CB3 fragment Asp-Gly-Glu-
Ala or DGEA) and investigated their polarization status after 6 days (Fig. S8 A and B). The 
cells cultured on DGEA-coated plates expressed higher levels of the M2 marker CD206, with 
no noticeable changes in the level of M1 marker expressions (in this case Calprotectin [5]), 
compared to BSA control group (Fig. S7 A) indicating a shift towards M2 phenotype in cells 
cultured on DGEA coated surfaces. Notably, cells cultured on DGEA-coated plates also 
demonstrated significantly higher levels of the anti-inflammatory cytokine, IL-10,  compared 
to the BSA control groups (Fig. S7 B) which again is an indication of a shift towards an M2 
phenotype[40]. This data also showed an increase in IL-6 production by cells on the DGEA-
coated plates. While IL-6 is typically considered as a pro-inflammatry cytokine, recent in vivo 
data has clearly shown that it also enhances the polarization of altenatively activated 
macrophages (i.e. M2 phenotype) [41]. Collectively, this data indicates that simple DGEA 
motives (which is recognized by integrin α2β1) induced a partial shift of human primary 
monocytes towards the M2 macrophage phenotype and created a cytokine environment that 
promoted M2 macrophages polarization, even in a 2D culture environment [41].  
By extension, this conclusion stipulates that poly(ethylene glycol) (PEG)-based 
hydrogels are bio-inert [42] and do not present integrin binding sites and are prone to cause M1 
macrophage polarization. Further studies with other bio-inert polymers can elucidate whether 
this conclusion can be generalized. Several such bio-inert biomaterials are often viewed as 
immunoprotective or immune-shielding. However, the inability of these materials to interact 
with immune cells (e.g., macrophages) in a direct manner can potentially drive the immune 
response in a deleterious direction. Indeed, these materials are more prone to deleterious 
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immune responses and result in relatively intense fibrous capsule formation upon implantation. 
This foreign body response is at least in part generated via M1 macrophages, which as resported 
in this work are generated when monocytes are unable to interact with the implant via integrins. 
Although the concept that the absence of a cell-biomaterial interaction can potently determine 
cell fates is novel, there is a well-established precedence within the domain of cell-cell 
interactions. In particular, our observations are reminiscent of the immunological failsafe that 
safeguards major histocompatibility complex (MHC) function. In this system, the immune 
system triggers programmed cell death of cells that present unfavorable antigens via their MHC 
[43]. Intuitively, it might therefore be expected that the absence of MHC expression might 
provide a degree of immunoprotection [44]. However, the immune system also triggers 
programmed cell death in cells that do not allow this interaction. Similarly, the immune system 
might attempt to destroy or isolate (via fibrous capsule formation) implants. In our study, we 
revealed that biomaterials designed to evade the immune system recognition by not presenting 
any integrin recognition motifs induce a pro-inflammatory M1 macrophage phenotype. It might 
therefore be reasoned that our immune system has evolved multiple distinct safeguards, which 
by default elicit a deleterious immune response when unable to interact with its target, be it a 
cell or biomaterial. In other words, the presence of encapsulated macrophages, acquiring an M2 
phenotype, in vivo can trigger a faster observation of the initial inflammation by facilitating the 
conversion of M1 macrophages to M2 macrophages. However, the complex nature of the in 
vivo implant microenvironment and the presence of other immune cells (such as T-cells) must 
be also taken into account and the means for long term cytokine induction (via controlled 
delivery systems) must be considered for potent in vivo effects. 
As such, biomaterial-based implants can be made truly immune-compatible by 
including motifs that prime the immune system to drive integration rather than rejection. 
Incorporating cell attachment sites into the design of biomaterials will thus not only stimulate 
the encapsulated therapeutic cells, but also steer the host’s immune system towards a healing 
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response. However, the amount of the inflammation must also be controlled; otherwise long-
term presence of M2 macrophages can result in fibrosis [45]. Indeed, recent studies have 
indicated that this approach is both feasible and practical; coating bio-inert biomaterials with 
decellularized ECM decreased M1 macrophage induction and the subsequent chronic 
inflammatory response [46]. Although our data indicated that integrin α2β1 played an essential 
role in M2 macrophage induction, other integrins could potentially affect macrophage 
proliferation distinctly as they interact with different ligands [47]. Indeed, decorating 
biomaterials with the integrin binding tripeptide Arg-Gly-Asp (RGD) has been reported to 
induce fibrosis [17b, 18c]. Systematic analysis of the effects of integrins, and other adhesive 
moieties, on macrophage polarity could resolve such contradictions and provide design 
principles on how to create next-generation biomaterials that controllably induce M1 or M2 
macrophage polarization. 
In summary, incorporating cell binding domains into biomaterials to facilitate integrin 
interactions in 3D microenvironment, such as those with α2β1, to steer the host’s immune 
system towards a natural healing response represents an exciting and novel opportunity to 
control and improve the clinical outcomes of biomaterial-based implants and cell therapies.  
 
3. Conclusion 
Biomaterial-mediated immunomodulation by programming macrophage polarity is a 
promising tool in tissue engineering, regenerative medicine, and implantology to decrease 
adverse immune reactions, accelerate implant integration, facilitate tissue regeneration, and 
increase implant lifetime. Here, we present a mechanism and 3D biomaterial-based approach 
for immunomodulation, which controls the balance between inducing pro-inflammatory M1 
macrophages and regenerative M2 macrophages. We have shown the ability of 3D encapsulated 
human monocytic THP-1 cells to interact with IL-4 stimulation and that the biomaterials 
through integrin α2β1 has a direct effect on macrophage phenotype by inducing M2 
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macrophages, whereas blocking this mechanism induces M1 macrophages. We have thereby 
further uncovered the essential and pivotal role of integrins in the immune response. Overall, 
biomaterial-based control over macrophages represents a novel technique to obtain a 
fundamental understanding of macrophage behavior and is a strong therapeutic tool for 
immunomodulation for implants, drug and cell delivery systems.  
 
4. Experimental section 
4.1 Biomaterials 
Polyethylene glycol diacrylate (PEGDA), gelatin (Type A, 300 bloom from porcine 
skin), and methacrylic anhydride (MA) were purchased from Sigma-Aldrich (Wisconsin, USA). 
Gelatin methacryloyl (GelMA) was synthesized as described previously [48]. Hydrogels were 
crosslinked using an UV source (Omnicure S2000, Ontario, Canada).  
 
4.2 Fabrication of hydrogel constructs 
Freeze dried prepolymer solutions were mixed in DPBS with 2-hydroxy-1-(4-
(hydroxyethoxy)phenyl)-2-methyl-1-propanone (Irgacure 2959, CIBA Chemicals) and placed 
at 80 °C until fully dissolved. Recombinant human IL-4 (R&D Systems) was added when 
desired at a final concentration of 10 ng/mL. Human monocytic THP-1 cells were encapsulated 
in the prepolymer at a final concentration of 6 × 106 cells per mL. Prepolymer samples were 
divided in 20 μL samples and photocrosslinked using 800 mW/cm2 UV light (Omnicure S2000, 
EXFO Photonic Solutions Inc.) for 10 or 40 seconds for GelMA and PEGDA hydrogels, 
respectively. Constructs were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco 
BRL) supplemented with 10% (v/v) fetal bovine serum (Gibco BRL) and 100 units/mL 
penicillin (Gibco BRL) in an incubator with 5% (v/v) CO2 at 37 °C. Medium was refreshed 
every two days.  
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4.3 Compressive modulus 
Two hundred microliters were formed and allowed to incubate at 37 °C in DPBS for 24 
hours. Hydrogels were tested at a rate of 20% strain/min on an Instron 5542 mechanical tester. 
The compressive modulus was determined as the slope of the linear region corresponding with 
0-5% strain. 
 
4.4 IL-4 release kinetics  
Hydrogels were submerged in 200 μL DPBS and incubated at 37 °C without agitation 
for up to 7 days. At predetermined time points, the supernatant was retrieved and replaced with 
fresh buffer. The IL-4 concentration in the supernatant was quantified using a human IL-4 
ELISA Kit (Quantikine® ELISA, R&D Systems).  
 
4.5  Viability and proliferation of human monocytic THP-1 cells 
24 hours post-encapsulation, live and dead cells were visualized using calcein-AM and 
ethidium homodimer (Invitrogen), photographed using an inverted fluorescence microscope 
(Nikon TE 2000-U), and quantified using NIH ImageJ software. Cell proliferation was 
measured up to 7 days of culture using Alamar Blue assay (Invitrogen).  
 
4.6 Hydrogel swelling analysis 
Polymerization was performed as described in section 4.2. Immediately following the 
hydrogel formation, discs (8mm in radius) of each composition was punched from a flat thin 
sheet and placed in DPBS at 37 °C for 24 hours. Discs were removed from DPBS and blotted 
with a KimWipe to remove the residual liquid and the swollen weight was recorded. Samples 
were then lyophilized and weighed once more to determine the dry weight of the polymer. The 
mass swelling ratio was then calculated as the ratio of swollen hydrogel mass to the mass of 
dry polymer. 
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4.7 Immunohistochemical staining 
Samples were fixed in 4% (v/v) formalin and permeabilized with 0.1% (v/v) Triton X-
100 for 30 minutes. Molecules of interest were labeled using a primary antibody such as Anti-
CD86 antibody (Abcam), anti-calprotectin antibody (Thermo Scientific), anti-mannose 
receptor antibody (CD206, Abcam), anti-vinculin antibody (Sigma), anti-NOS2 antibody 
(Santa Cruz Biotechnology), and anti-Arginase-1 antibody (Santa Cruz Biotechnology). Target 
molecules were then visualized using Alexa 488 or Alexa 594 conjugated secondary antibodies 
(Molecular Probes). F-Actin was visualized using rhodamine-phalloidin (Invitrogen). Samples 
were counterstained with 4, 6-diamidino-2-phenylindole (DAPI, Vector Laboratories Inc.) and 
photographed using either a fluorescence microscope (IX71 inverted microscope, Olympus) or 
an inverted laser scanning confocal microscope (SP5 X MP, Leica Microsystems). Signal 
intensities of CD86, CD206, iNOS, and arginase-1 of individual cells were quantitatively 
analyzed using NIH ImageJ software. 
 
4.8 Quantitative real-time PCR  
Total RNA was extracted using TRIzol (Invitrogen), quantified using a Nanodrop2000 
(Thermo Fisher Scientific), and synthesized into cDNA synthesis using SuperScript™ III First-
Strand Synthesis SuperMix (Invitrogen). For quantitative real-time PCR analysis, 20 ng of input 
RNA was amplified in an IQ5 detection system (Biorad) using SYBR Green Master Mix (Bio-
Rad) and 500 nmol/L of gene-specific primers. All mRNA expression levels were normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences are listed in 
Supplementary table 1.  
 
4.9 Cytokine expression profiling 
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Hydrogels embedded THP-1 cellswere cultured for 6 days after which fresh medium 
was allowed to be conditioned for 24 hours and laden onto a human cytokine antibody array 
(Human Cytokine Array C6, RayBiotech Inc), processed, and detected according to 
manufacturer’s protocol. Invariant set normalization was used to normalize the inter-array 
intensity (Image pro PLUS, Media Cybermetics Inc.). 
 
4.10 Integrin receptor blocking  
Human monocytic THP-1 cells were pretreated with 10 μg/mL Anti-Integrin alpha 
2+beta 1 antibody (Abcam) or non-inhibitory isotype control antibody (Abcam) for 30 minutes 
at 37 °C, washed, encapsulated in GelMA hydrogels containing IL-4, and cultured for 6 days. 
 
4.11 Nitrite production 
After 6 days of culture, 50 μL of supernatant was retrieved and proceed according to 
manufacturer’s protocols (Griess reagent, Promega). The absorbance of the developed solution 
was measured at a wavelength of 550 nm using an ELISA Microplate Reader (VersaMax, 
Molecular Device).  
 
4.12 Fabrication of α2β1 integrin ligand peptide Asp-Gly-Glu-Ala (DGEA) coated substrate 
      To prepare the DGEA coated coverslips, acid-etched glass coverslips were incubated with 
0.1 mg/ml MAPTrix™-C-DGEA peptide (Amsbio) or bovine serum albumin (BSA) (used as a 
negative control) in 500 mM NaHCO3 solution for 1 hour at room temperature. Coverslips were 
washed with PBS and used immediately. Buffy coat samples were obtained from healthy 
volunteers in accordance with the relevant guidelines after obtaining informed written consent 
and approval of local ethics committee (all approved by the National Blood Service, UK). 
Human peripheral blood mononuclear cells (PBMCs) were obtained from heparinised blood by 
Histopaque-1077 density gradient centrifugation. Monocytes were isolated from PBMCs using 
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the Miltenyi Biotec magnetic cell separation system (positive selection with CD14 MicroBeads 
and LS columns) as per the manufacturer’s instructions. This method yielded 95% pure 
monocytes as determined by flow cytometric analysis of CD14 expression. Purified monocytes 
were cultured at 5 x 105 cells/coverslip in RPMI-1640 supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin (referred to henceforth as “RPMI 
complete medium”) and 10 ng/ml Macrophage-Colony Stimulating Factor (M-CSF) (Miltenyi 
Biotec) in 24-well tissue culture-treated plates. Included controls were: M1 (50 ng/mL 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Miltenyi Biotec) + 20 ng/mL 
IFN-γ (R&D Systems)), M2 (50 ng/mL M-CSF + 20 ng/mL IL-4 (Miltenyi Biotec)), and M-
CSF (10 ng/mL M-CSF). Samples were incubated at 37°C, 5% CO2 for 6 days, with fresh 
complete medium containing cytokines added on Day 3. On Day 6, samples were stained with 
1 μg/mL rabbit anti-human mannose receptor antibody (Abcam) and 2 μg/mL mouse anti-
human calprotectin antibody (Thermo Scientific) (M2 and M1 markers respectively [5]) diluted 
in 5% goat serum in PBS. Secondary antibody staining was then carried out using 8 μg/mL each 
of goat anti-rabbit Alexa Fluor® 488-conjugated antibody and goat anti-mouse Rhodamine 
Red-X-conjugated antibody (both from Thermo Fisher Scientific). Finally, samples were 
counterstained with 250 ng/mL DAPI and mounted on microscope slides. Images were captured 
using an IMSTAR automated fluorescence microscope. Image analysis and quantification was 
carried out using CellProfiler software v 2.1.1. Furthermore, supernatants were collected and 
assayed for the cytokines IL-6 and IL-10 using ELISA DuoSet kits (R&D Systems) as per the 
manufacturer’s instructions. 
 
4.13 Statistical analysis 
At least three independent sets of experiments for each condition were performed in 
triplicate. Data were pooled and statistically expressed as mean ± standard deviation (S.D). 
Two-way analysis of variance (ANOVA) was used for analysis of quantitative values, and 
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Tukey’s post hoc test was used for all pair-wise comparisons among groups. Differences were 
considered significant at p < 0.05 and were indicated with an asterisk. The SPSS software 
package (version 12.0; SPSS Inc.) was used to perform statistical tests.  
 
Supporting Information 
Supporting Information is available from the Wiley Online Library or from the author. 
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Figure 1. Characterization of 3D encapsulated human monocytic THP-1 cells behavior in 
IL-4 incorporated PEGDA and GelMA hydrogels for 6 days. (A) THP-1 cells  morphology 
in IL-4 cytokine incorporated PEGDA and GelMA hydrogels. (B) Quantitation of cellsdiameter 
in IL-4 cytokine incorporated PEGDA or GelMA hydrogel. (C) Distribution of cell diameter in 
IL-4 cytokine incorporated PEGDA and GelMA hydrogels. (D) Micrographs of cellsin 
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hydrogel constructs stained for M1 surface marker CD86 (red) and M2 surface marker CD206 
(green). Scale bar represents 100 µm. (E) Quantitative analysis of micrographs. (F) Real-time 
PCR of M1 related IRF5 and IL6 and (G) M2 related STAT6 and IL10. Scale bar represents 100 
µm. The data are shown as the mean ± SEM (*, p < 0.05). 
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Figure 2. In vitro immune response of human monocytic THP-1 cells encapsulated in 
PEGDA and GelMA hydrogels in the absence or presence of IL-4 for 6 days. (A) Real-time 
PCR of inflammatory genes. (B) Biochemical quantification of nitrite production. (C) 
Micrographs of THP-1 cells fluorescently stained for M1 related iNOS, M2 related Arginase-1 
and DAPI. (D) Quantitative analysis of micrographs. Scale bar represents 100 µm. The data are 
shown as the mean ± SEM (*, p < 0.05). 
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Figure 3. Pro- and anti-inflammatory cytokine release of human monocytic THP-1 cells in 
IL-4 incorporated PEGDA and GelMA hydrogels for 6 days. (A and C) Cytokine release 
assay and its (B and D) Quantitative analysis of THP-1 cellsexposed to both M1 inducing 
lipopolysaccharides (LPS) and M2 macrophage inducing IL-4 in PEGDA and GelMA 
hydrogels. The data are shown as the mean ± SEM (*, p < 0.05). 
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Figure 4. Changes in cytoskeletal organization and focal adhesion molecules in IL-4 
cytokine incorporated PEGDA and GelMA hydrogels for 6 days. (A) Real-time PCR of 
protein tyrosine kinase 2 (PTK2) and Vinculin (VCL). (B) Real-time PCR of monocyte related 
integrin receptors (Integrin αD (ITGAD) and Integrin β2(ITGB2)). (C) Real-time PCR of 
collagen matrix related integrin receptors (Integrin α2 (ITGA2) and Integrin β1 (ITGB1)). (D) 
Micrographs of F-Actin and Vinculin of THP-1 cells encapsulated in IL-4 cytokine 
incorporated PEGDA and GelMA hydrogels. Scale bar represents 10 µm. The data are shown 
as the mean ± SEM (*, p < 0.05). 
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Figure 5. The effect of integrin α2β1 inhibition on macrophage polarity in IL-4 cytokine 
incorporated GelMA hydrogel. (A) Confocal images of M1 and M2 macrophage surface 
markers CD86 and CD206 with or without integrin α2β1 receptor inhibitor or non-inhibitory 
isotype control antibody. Scale bar represents 100 µm. (B) Quantitative analysis of micrographs. 
(C) Confocal images of focal adhesion molecule expression with or without integrin α2β1 
receptor inhibitor. Scale bar represents 10 µm. (D) mRNA expression levels of M1 and M2 
macrophage markers and focal adhesion molecules in IL-4 incorporated GelMA hydrogel with 
or without integrin α2β1 receptor inhibitor. (E) Proposed mechanism via which biomaterials 
are able to prime human monocytic THP-1 cells into either a M1 or M2 macrophage phenotype. 
The data are shown as the mean ± SEM (*, p < 0.05). 
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Supplemental table 1. Nucleotide sequences of the primer pairs used for qPCR in this study.  
Gene Human primer sequence 
Product size 
(bp) 
IRF5 75 bp 
Sense 5’- CCA GCC AGG ACG GAG ATA AC -3’  
Antisense 5’- CAT CCA CGC CTT CGG TGT AT -3’  
STAT6 235 bp 
Sense 5’- ATG GGG CAA CAG AAA AGA TG -3’  
Anisense 5’- GCA CAG AAG ACA GCA GCA AG -3’  
IL6  49 bp 
Sense 5’- ACT CAC CTC TTC AGA ACG AAT TG -3’  
Antisense 5’- GTC GAG GAT GTA CCG AAT TTG T -3’  
IL10 112 bp 
Sense 5’- GAC TTT AAG GGT TAC CTG GGT TG -3’  
Antisense 5’- TCA CAT GCG CCT TGA TGT CTG -3’  
NOS2 117 bp 
Sense 5’- ATT CAC TCA GCT GTG CAT CG -3’  
Antisense 5’- TCA GGT GGG ATT TCG AAG AG -3’  
NFKB1 103 bp 
Sense 5’- TGA GTC CTG CTC CTT CCA -3’  
Antisense 5’- GCT TCG GTG TAG CCC ATT -3’  
TNFA 93 bp 
Sense 5’- CTG CTG CAC TTT GGA GTG AT -3’  
Antisense 5’- AGA TGA TCT GAC TGC CTG GG -3’  
PTK2 177 bp 
Sense 5’- AGT TTC CCC AGA GCT CCT CA -3’  
Antisense 5’- TAC TCG CTC CAT TGC ACC AG -3’  
VCL  95 bp 
Sense 5’- CGA TTA CGA ACC TGA GCT GC -3’  
Antisense 5’- TGG TAG CTT CCC GAT GCA AG -3’  
ITGA2 154 bp 
Sense 5’- GGA ACG GGA CTT TCG CAT -3’  
Antisense 5’- GGT ACT TCG GCT TTC TCA TCA -3’  
ITGAD 133 bp 
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Sense 5’- CAT GAG ATT CAG CCC TGT GGA -3’  
Antisense 5’- GTC ACC TAG CTG GTC CAG TG -3’  
ITGB1 150 bp 
Sense 5’- CCG CGC GGA AAA GAT GAA T -3’  
Antisense 5’- CCA CAA TTT GGC CCT GCT TG -3’  
ITGB2 102 bp 
Sense 5’- GGT GCA ACC CAC CAC TTC CT -3’  
Antisense 5’- CCT GGG TCA CGT CTA GAA ACC -3’  
GAPDH 143 bp 
Sense 5’- ACA TCG CTC AGA CAC CAT G -3’  
Antisense 5’- TGT AGT TGA GGT CAA TGA AGG G -3’  
bp: base pair 
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Figure S1. Compressive modulus of 5, 10, and 15% GelMA hydrogel. The data are shown as 
the mean ± SEM (*, p < 0.05). 
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Figure S2. (A) Human monocytic THP-1 cell  viability in 5, 10, and 15% GelMA hydrogels 
24 hours post-encapsulation. (B) Quantification of cell viability demonstrated excellent cell 
survival in 5% GelMA. Scale bar represents 100 µm. The data are shown as the mean ± SEM 
(*, p < 0.05). 
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Figure S3. THP-1 cellsmetabolic activity in 5, 10, and 15% GelMA hydrogels over a period of 
7 days. The data are shown as the mean ± SEM (*, p < 0.05; compared to both 10 and 15% 
GelMA). 
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Figure S4. (A) Swelling properties of 5, 10, and 15% GelMA hydrogels over a period of 7 days. 
The swelling ratios of GelMA hydrogels at various GelMA % (w/v) show statistically 
significant differences. The data are shown as the mean ± SEM (*, p < 0.05; compared to both 
10 and 15% GelMA, §, p < 0.05; compared to both 5 and 15% GelMA). (B) Swelling properties 
of 10% PEGDA and 5% GelMA hydrogels over a period of 5 days. The swelling ratios between 
PEGDA and GelMA hydrogels show no significant differences. 
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Figure S5. IL-4 cytokine release from 5, 10, and 15% GelMA hydrogels. The data are shown 
as the mean ± SEM (*, p < 0.05; compared to both 10 and 15% GelMA). 
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Figure S6. Compressive modulus of PEGDA and GelMA hydrogels with or without of 
incorporated IL-4. 
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Figure S7. IL-4 cytokine release profile when incorporated in PEGDA and GelMA hydrogels.  
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Figure S8. The effects of α2β1 integrin peptide on human primary 
monocytes‘ differentiation. (A) Micrographs of macrophages fluorescently stained for M1 
marker Calprotectin, M2 marker CD206, and DAPI. Scale bar represents 200 µm. (B) IL-6 and 
IL-10 cytokine release profile as measured by ELISA. The data are shown as the mean ± SEM 
(*, p < 0.05). 
 
